Literature DB >> 26973218

Tailor-made heart simulation predicts the effect of cardiac resynchronization therapy in a canine model of heart failure.

Nirmal Panthee1, Jun-ichi Okada2, Takumi Washio2, Youhei Mochizuki3, Ryohei Suzuki3, Hidekazu Koyama3, Minoru Ono1, Toshiaki Hisada2, Seiryo Sugiura4.   

Abstract

Despite extensive studies on clinical indices for the selection of patient candidates for cardiac resynchronization therapy (CRT), approximately 30% of selected patients do not respond to this therapy. Herein, we examined whether CRT simulations based on individualized realistic three-dimensional heart models can predict the therapeutic effect of CRT in a canine model of heart failure with left bundle branch block. In four canine models of failing heart with dyssynchrony, individualized three-dimensional heart models reproducing the electromechanical activity of each animal were created based on the computer tomographic images. CRT simulations were performed for 25 patterns of three ventricular pacing lead positions. Lead positions producing the best and the worst therapeutic effects were selected in each model. The validity of predictions was tested in acute experiments in which hearts were paced from the sites identified by simulations. We found significant correlations between the experimentally observed improvement in ejection fraction (EF) and the predicted improvements in ejection fraction (P<0.01) or the maximum value of the derivative of left ventricular pressure (P<0.01). The optimal lead positions produced better outcomes compared with the worst positioning in all dogs studied, although there were significant variations in responses. Variations in ventricular wall thickness among the dogs may have contributed to these responses. Thus CRT simulations using the individualized three-dimensional heart models can predict acute hemodynamic improvement, and help determine the optimal positions of the pacing lead.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart block; Heart failure; Multi-scale simulation; Pacemakers

Mesh:

Year:  2016        PMID: 26973218     DOI: 10.1016/j.media.2016.02.003

Source DB:  PubMed          Journal:  Med Image Anal        ISSN: 1361-8415            Impact factor:   8.545


  6 in total

Review 1.  Species-Dependent Mechanisms of Cardiac Arrhythmia: A Cellular Focus.

Authors:  Andrew G Edwards; William E Louch
Journal:  Clin Med Insights Cardiol       Date:  2017-02-02

2.  Absence of Rapid Propagation through the Purkinje Network as a Potential Cause of Line Block in the Human Heart with Left Bundle Branch Block.

Authors:  Jun-Ichi Okada; Takumi Washio; Machiko Nakagawa; Masahiro Watanabe; Yoshimasa Kadooka; Taro Kariya; Hiroshi Yamashita; Yoko Yamada; Shin-Ichi Momomura; Ryozo Nagai; Toshiaki Hisada; Seiryo Sugiura
Journal:  Front Physiol       Date:  2018-02-06       Impact factor: 4.566

Review 3.  Computational Modeling for Cardiac Resynchronization Therapy.

Authors:  Angela W C Lee; Caroline Mendonca Costa; Marina Strocchi; Christopher A Rinaldi; Steven A Niederer
Journal:  J Cardiovasc Transl Res       Date:  2018-01-11       Impact factor: 4.132

4.  Patient-specific heart simulation can identify non-responders to cardiac resynchronization therapy.

Authors:  Akihiro Isotani; Kazunori Yoneda; Takashi Iwamura; Masahiro Watanabe; Jun-Ichi Okada; Takumi Washio; Seiryo Sugiura; Toshiaki Hisada; Kenji Ando
Journal:  Heart Vessels       Date:  2020-03-12       Impact factor: 2.037

Review 5.  Clinical and pharmacological application of multiscale multiphysics heart simulator, UT-Heart.

Authors:  Jun-Ichi Okada; Takumi Washio; Seiryo Sugiura; Toshiaki Hisada
Journal:  Korean J Physiol Pharmacol       Date:  2019-08-26       Impact factor: 2.016

Review 6.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.